Cargando…

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review

Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer among women worldwide, with the 5-year survival rate ranging between 30 and 40%. Due to the asymptomatic nature of the condition, it is more likely to be diagnosed at an advanced stage, requiring an aggressive therapeutic appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nag, Shona, Aggarwal, Shyam, Rauthan, Amit, Warrier, Narayanankutty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331490/ https://www.ncbi.nlm.nih.gov/pubmed/35902911 http://dx.doi.org/10.1186/s13048-022-01020-1

Ejemplares similares

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
por: Gupta, Sudeep, et al.
Publicado: (2019)

Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis
por: Xu, Xiaoyu, et al.
Publicado: (2019)

Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
por: Lee, Banghyun, et al.
Publicado: (2023)

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
por: DiSilvestro, Paul, et al.
Publicado: (2021)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

Poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis
por: Cheng, Hongyan, et al.
Publicado: (2021)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
por: Srinivasan, K. N, et al.
Publicado: (2014)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2023)

Under-Treatment of Older Patients with Newly Diagnosed Epithelial Ovarian Cancer Remains an Issue
por: Dumas, Lucy, et al.
Publicado: (2021)

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2022)

Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis
por: Gulia, S., et al.
Publicado: (2022)

Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials
por: Wang, Yizi, et al.
Publicado: (2021)

Maintenance therapy with a poly (ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: updated individual patient data and trial-level meta-analysis
por: Gulia, S., et al.
Publicado: (2022)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

A Case Report of Newly Diagnosed Epithelial Ovarian Carcinoma Presenting with Spontaneous Tumor Lysis Syndrome and Its Successful Management with Rasburicase
por: Shukla, Deepak Kumar, et al.
Publicado: (2017)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer
por: Lorusso, Domenica, et al.
Publicado: (2022)

Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
por: Bird, Sarah A., et al.
Publicado: (2020)

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
por: Colombo, Nicoletta, et al.
Publicado: (2021)

Current status of maintenance therapy for advanced ovarian cancer
por: Hope, Joanie Mayer, et al.
Publicado: (2010)

To Bev or Not to Bev during Ovarian Cancer Maintenance Therapy?
por: Sznurkowski, Jacek Jan
Publicado: (2023)

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
por: Fujiwara, Keiichi, et al.
Publicado: (2021)

Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences
por: Shen, Yuanming, et al.
Publicado: (2022)

Targeted Therapies in Epithelial Ovarian Cancer
por: Dean, Emma, et al.
Publicado: (2010)

Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer
por: Kim, Soyoun Rachel, et al.
Publicado: (2021)

Targeted Therapies in Epithelial Ovarian Cancer
por: Barrena Medel, Nicanor I., et al.
Publicado: (2010)

Antivascular Therapy for Epithelial Ovarian Cancer
por: Duhoux, Francois P., et al.
Publicado: (2010)

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides
por: Xu, Benyong, et al.
Publicado: (2019)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Laser Interstitial Thermal Therapy in Patients with Newly Diagnosed Glioblastoma: A Systematic Review
por: Viozzi, Ilaria, et al.
Publicado: (2021)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review
por: Smith, Haller J., et al.
Publicado: (2017)

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy
por: Jackson, Graham, et al.
Publicado: (2019)

Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments
por: Lokadasan, Rajitha, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer
por: Badora-Rybicka, Agnieszka, et al.
Publicado: (2016)

Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study)
por: Liontos, Michalis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bb2cbrqir6lt770696f8dahu04